I'm A Patient
I'm A ProviderMore Than 200 Million People Live with Dry AMD Worldwide
Until now, there has never been a proven solution to improve vision loss from dry AMD. MacuMira changes that.
MacuMira is Canada’s first and only clinically proven treatment for dry age-related macular degeneration. This safe, painless, noninvasive therapy can be delivered in short appointments at local eye care clinics. Clinical results showed patients experienced improved visual clarity in just 10 days.
Discover how MacuMira is helping Canadians living with dry AMD see more clearly.
Learn More About MacuMira for Dry AMD
MacuMira: Changing the Story of Dry AMD
Dry age-related macular degeneration (AMD) doesn’t just affect your vision; it affects how you live. From losing independence to missing out on everyday details, the impact can be profound.
Historically, management focused only on slowing progression. Now, with MacuMira, there’s a clinically supported way to help improve how you see.
MacuMira is a first-of-its-kind solution authorized by Health Canada to improve visual function in people living with dry AMD. It’s safe, comfortable, and designed to fit easily into the clinical care experience.
Your sight and your quality of life matter. MacuMira is here to support you every step of the way.
How MacuMira Works
Microcurrent Stimulation
MacuMira delivers low-level microcurrent through the eyelids to stimulate retinal activity. This approach is grounded in decades of medical use and has been adapted for the specific needs of dry AMD.
Clinically Improved Vision
A clinical trial demonstrated that 100% of patients experienced improved visual function after receiving 6 treatments over a 30-week period. On average, patients showed improved visual acuity (as assessed by the ETDRS, which measures the number of letters read) and contrast sensitivity within 4 weeks of the first treatment. With continued treatment, vision may be maintained indefinitely.
Noninvasive & Comfortable
MacuMira requires no injections, medication, lasers, or surgery. Patients simply visit their eye care provider on a prescribed schedule, relax while wearing the MacuMira device for approximately half an hour, and then continue with their day.
Download the Clinical Trial
The MacuMira clinical trial, published in the International Journal of Retina and Vitreous, found the following:
100%
of patients in the treatment group showed improved vision
48%
of patients improved by at least 10 letters on the ETDRS acuity chart
8.2 ETDRS letters
Average improvement, along with a 25% average increase in ETDRS acuity
0
adverse effects of treatment
100%
of treated patients maintained their vision improvements for the duration of the trial
Articles
Understanding how dry AMD affects you or your family member can make it a little easier to navigate. Learn more about this eye disease in our articles.
Your Guide to Dry Age-related Macular Degeneration: Key Treatments and Care Strategies
BlogDry age-related macular degeneration (AMD) is a progressive eye condition that affects the macula, leading to gradual central vision loss. As the most common form of AMD, it typically develops slowly. Early detection and management are crucial for maintaining eye health. Understanding In dry AMD, the macula thins over time, often accompanied by the formation of […]
Can Wet Macular Degeneration Turn Into Dry Macular Degeneration?
BlogAge-related macular degeneration (AMD) is one of the leading causes of vision loss in older adults. It comes in two forms: dry (atrophic) and wet (neovascular). While dry AMD progresses gradually over time, wet AMD can cause sudden and severe vision loss. A common question among patients and caregivers is whether wet macular degeneration can turn […]
Read More… from Can Wet Macular Degeneration Turn Into Dry Macular Degeneration?
What is geographic atrophy (GA)?
BlogHow it’s related to dry AMD and who’s the most at risk For those with dry age-related macular degeneration (dry AMD), there’s always a risk that this condition could develop into geographic atrophy (GA), a condition where retinal pigment epithelial (RPE) cells start to die off. Research estimates that there are approximately 180,000 new cases of GA […]
Your Guide to Dry Age-related Macular Degeneration: Key Treatments and Care Strategies
Dry age-related macular degeneration (AMD) is a progressive eye condition that affects the macula, leading to gradual central vision loss. As the most common form of AMD, it typically develops slowly. Early detection and management are crucial for maintaining eye health. Understanding In dry AMD, the macula thins over time, often accompanied by the formation of […]
Can Wet Macular Degeneration Turn Into Dry Macular Degeneration?
Age-related macular degeneration (AMD) is one of the leading causes of vision loss in older adults. It comes in two forms: dry (atrophic) and wet (neovascular). While dry AMD progresses gradually over time, wet AMD can cause sudden and severe vision loss. A common question among patients and caregivers is whether wet macular degeneration can turn […]
Read More… from Can Wet Macular Degeneration Turn Into Dry Macular Degeneration?
What is geographic atrophy (GA)?
How it’s related to dry AMD and who’s the most at risk For those with dry age-related macular degeneration (dry AMD), there’s always a risk that this condition could develop into geographic atrophy (GA), a condition where retinal pigment epithelial (RPE) cells start to die off. Research estimates that there are approximately 180,000 new cases of GA […]
Patients
Eye Care Providers
Select your Country
Corporate:
#302, 815 – 1st Street SW
Calgary, AB
T2P 1N3
info@macumira.com
1-844-619-6263
Mailing Address:
MacuMira Medical Devices Inc
#136 1811 4th Street SW
Calgary, AB
T2S 1W2
Hours:
Mon-Fri: 8am – 5pm
Sat – Sun: Closed